eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

3/2018
vol. 43
 
Share:
Share:
more
 
 
abstract:
Clinical immunology

Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis

Dorota Sikorska, Rafał Rutkowski, Joanna Łuczak, Włodzimierz Samborski, Janusz Witowski

(Centr Eur J Immunol 2018; 43 (3): 289-294)
Online publish date: 2018/10/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
While adiponectin is typically viewed as an anti-inflammatory mediator, such an activity of adiponectin in rheumatoid arthritis (RA) is not so obvious. In the present study we examined whether serum levels of adiponectin reflect the clinical phenotype of RA patients and/or correlate with severity of the disease and the response to anti-TNF-α therapy.

Material and methods
Twenty-one female RA patients qualified to receive anti-TNF-α treatment were prospectively assessed before and after 12 weeks of therapy. Patients underwent full clinical and biochemical assessment. Disease activity was assessed by the Modified Disease Activity Scores (DAS28). Serum concentrations of adiponectin were measured with an immunoassay. The individuals were divided into two subgroups according to whether their baseline serum adiponectin was below or above the median value. The subgroups did not differ in basic demographic, anthropometric, and clinical parameters.

Results
Anti-TNF-α treatment resulted in a significant clinical (DAS28) improvement in patients from both subgroups, but no significant differences between basal and post-treatment serum adiponectin concentrations were observed. However, patients with higher baseline adiponectin experienced a significant and more pronounced improvement in laboratory parameters of inflammation (ESR, CRP, neutrophil count, neutrophil-to-lymphocyte ratio).

Conclusions
It is possible that adiponectin exerts systemic anti-inflammatory effects independently of the local activity of RA.

keywords:

rheumatoid arthritis, inflammation, adiponectin, adipocytokines, anti-TNF-α treatment

references:
Neumann E, Junker S, Schett G, et al. (2016): Adipokines in bone disease. Nat Rev Rheumatol 12: 296-302.
Liu D, Luo S, Li Z (2015): Multifaceted roles of adiponectin in rheumatoid arthritis. Int Immunopharmacol 28: 1084-1090.
Toussirot E, Michel F, Binda D, Dumoulin G (2015): The role of leptin in the pathophysiology of rheumatoid arthritis. Life Sci 140: 29-36.
Abella V, Scotece M, Conde J, et al. (2017): Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol 13: 100-109.
Muller-Ladner U, Neumann E. (2009): Rheumatoid arthritis: the multifaceted role of adiponectin in inflammatory joint disease. Nat Rev Rheumatol 5: 659-660.
Chen X, Lu J, Bao J, et al. (2013): Adiponectin: a biomarker for rheumatoid arthritis? Cytokine Growth Factor Rev 24: 83-89.
Fasshauer M, Bluher M (2015): Adipokines in health and disease. Trends Pharmacol Sci 36: 461-470.
Scotece M, Conde J, Lopez V, et al. (2014): Adiponectin and leptin: new targets in inflammation. Basic Clin Pharmacol Toxicol 114: 97-102.
Ehling A, Schaffler A, Herfarth H, et al. (2006): The potential of adiponectin in driving arthritis. J Immunol 176: 4468-4478.
Senolt L, Pavelka K, Housa D, Haluzik M (2006): Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 35: 247-252.
Ozgen M, Koca SS, Dagli N, et al. (2010): Serum adiponectin and vaspin levels in rheumatoid arthritis. Arch Med Res 41: 457-463.
Alkady EA, Ahmed HM, Tag L, Abdou MA (2011): [Serum and synovial adiponectin, resistin, and visfatin levels in rheumatoid arthritis patients. Relation to disease activity]. Z Rheumatol 70: 602-608.
Lee YH, Bae SC (2018): Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis. Int J Rheum Dis 21: 664-672.
Cao H, Lin J, Chen W, et al. (2016): Baseline adiponectin and leptin levels in predicting an increased risk of disease activity in rheumatoid arthritis: A meta-analysis and systematic review. Autoimmunity 49: 547-553.
Targonska-Stepniak B, Dryglewska M, Majdan M (2010): Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. Rheumatol Int 30: 731-737.
Li P, Yang L, Ma CL, et al. (2015): Low-molecular-weight adiponectin is more closely associated with disease activity of rheumatoid arthritis than other adiponectin multimeric forms. Clin Rheumatol 34: 1025-1030.
Klein-Wieringa IR, van der Linden MP, Knevel R, et al. (2011): Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 63: 2567-2574.
Meyer M, Sellam J, Fellahi S, et al. (2013): Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther 15: R210.
Ibrahim SM, Hamdy MS, Amer N (2008): Plasma and synovial fluid adipocytokines in patients with rheumatoid arthritis and osteoarthritis. Egypt J Immunol 15: 159-170.
Klaasen R, Herenius MM, Wijbrandts CA, et al. (2012): Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis 71: 1510-1516.
Engvall IL, Tengstrand B, Brismar K, Hafstrom I (2010): Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 12: R197.
Popa C, Netea MG, de Graaf J, et al. (2009): Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 36: 724-730.
Aletaha D, Neogi T, Silman AJ, et al. (2010): rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-1588.
van Gestel AM, Prevoo ML, van ‚t Hof MA, et al. (1996): Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39: 34-40.
Smolen JS, Landewe R, Breedveld FC, et al. (2014): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492-509.
Prevoo ML, van ‚t Hof MA, Kuper HH, et al. (1995): Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
Yoshino T, Kusunoki N, Tanaka N, et al. (2011): Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis. Intern Med 50: 269-275.
Toussirot E, Binda D, Gueugnon C, Dumoulin G (2012): Adiponectin in autoimmune diseases. Curr Med Chem 19: 5474-5480.
Fantuzzi G (2008): Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 121: 326-330.
Kim KS, Choi HM, Ji HI, et al. (2014): Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment. Mol Med Rep 9: 255-260.
Ferraz-Amaro I, Arce-Franco M, Muniz J, et al. (2011): Systemic blockade of TNF-αlpha does not improve insulin resistance in humans. Horm Metab Res 43: 801-808.
Kontny E, Zielinska A, Ksiezopolska-Orlowska K, Gluszko P (2016): Secretory activity of subcutaneous abdominal adipose tissue in male patients with rheumatoid arthritis and osteoarthritis – association with clinical and laboratory data. Reumatologia 54: 227-235.
Haugen F, Drevon CA (2007): Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 148: 5478-5486.
Korybalska K, Swora-Cwynar E, Luczak J, et al. (2016): Association of endothelial proliferation with the magnitude of weight loss during calorie restriction. Angiogenesis 19: 407-419.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe